Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

被引:18
|
作者
Xu, Xi [1 ,2 ]
Ren, Jie [1 ,2 ]
Ma, Yinghe [1 ,2 ]
Liu, Hongting [1 ]
Rong, Quanjin [1 ]
Feng, Yifan [1 ]
Wang, Yameng [1 ]
Cheng, Yu [1 ]
Ge, Ruijia [3 ]
Li, Zhiyu [1 ,2 ]
Bian, Jinlei [1 ,2 ]
机构
[1] China Pharmaceut Univ, State Key Lab Nat Med, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Jiangsu, Peoples R China
[2] China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing, Jiangsu, Peoples R China
[3] Madeira Sch, Mclean, VA USA
基金
美国国家科学基金会; 中国国家自然科学基金;
关键词
Indoleamine 2,3-dioxygenase 1; inhibitor; virtual screen; cyanopyridine scaffold; hit optimisation; INDOLEAMINE 2,3-DIOXYGENASE; TRYPTOPHAN DEGRADATION; CRYSTAL-STRUCTURES; POTENT INHIBITORS; MOLECULAR DOCKING; DETAILED ANALYSIS; DENDRITIC CELLS; DERIVATIVES; DESIGN; EXPRESSION;
D O I
10.1080/14756366.2018.1480614
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.
引用
收藏
页码:250 / 263
页数:14
相关论文
共 50 条
  • [21] Discovery of Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 Through Structure-Based Virtual Screening
    Zhang, Guoqing
    Xing, Jing
    Wang, Yulan
    Wang, Lihao
    Ye, Yan
    Lu, Dong
    Zhao, Jihui
    Luo, Xiaomin
    Zheng, Mingyue
    Yan, Shiying
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [22] Discovery and preliminary structure-activity relationship of 1H-indazoles with promising indoleamine-2,3-dioxygenase 1 (IDO1) inhibition properties
    Qian, Shan
    He, Tao
    Wang, Wei
    He, Yanying
    Zhang, Man
    Yang, Lingling
    Li, Guobo
    Wang, Zhouyu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (23) : 6194 - 6205
  • [23] Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1)
    Roehrig, Ute F.
    Michielin, Olivier
    Zoete, Vincent
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (24) : 17690 - 17705
  • [24] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
    Tang, Kai
    Wu, Ya-Hong
    Song, Yihui
    Yu, Bin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [25] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
    Moyer, Benjamin J.
    Rojas, Itzel Y.
    Murray, Iain A.
    Lee, Seokwon
    Hazlett, Haley F.
    Perdew, Gary H.
    Tomlinson, Craig R.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 323 : 74 - 80
  • [26] Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
    Kai Tang
    Ya-Hong Wu
    Yihui Song
    Bin Yu
    Journal of Hematology & Oncology, 14
  • [27] Carborane-Containing Hydroxyamidine Scaffolds as Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 (IDO1)
    Austin, Christopher J. D.
    Moir, Michael
    Kahlert, Jan
    Smith, Jason R.
    Jamie, Joanne F.
    Kassiou, Michael
    Rendina, Louis M.
    AUSTRALIAN JOURNAL OF CHEMISTRY, 2015, 68 (12) : 1866 - 1870
  • [28] Development of 2" generation indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitors
    Pesnot, Thomas
    Mahale, Sachin
    MacFaul, Philip
    Maclean, John
    Phillips, Caroline
    Bingham, Matilda
    Eagle, Catherine
    Kelly, James
    Thippeswamy, Abhijith
    Armitage, Simon
    Grisin, Aleksandr
    Aiken, Sheenagh
    Cartwright, Lucy
    Armer, Richard
    CANCER RESEARCH, 2017, 77
  • [29] Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy
    Weng, Tianwei
    Qiu, Xiaqiu
    Wang, Jubo
    Li, Zhiyu
    Bian, Jinlei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 143 : 656 - 669
  • [30] Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors
    Jung, Juyoung
    Yoon, Hongchul
    Sohn, Te-ik
    Jang, Kyusic
    Yoo, Yeongran
    Jeong, Ilji
    Shin, Jae Eui
    Lee, Jin Hee
    Ann, Jihyae
    Lee, Jeewoo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 40